NASDAQ:BVXV - BIONDVAX PHARMA/S Stock Price, Forecast & News

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

BIONDVAX PHARMA/S (NASDAQ:BVXV) released its quarterly earnings data on Tuesday, November, 26th. The company reported ($0.57) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.54. View BIONDVAX PHARMA/S's Earnings History.

BIONDVAX PHARMA/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for BIONDVAX PHARMA/S.

Media headlines about BVXV stock have trended positive on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIONDVAX PHARMA/S earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for BIONDVAX PHARMA/S.

BIONDVAX PHARMA/S saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 29,700 shares, an increase of 364.1% from the December 15th total of 6,400 shares. Based on an average daily trading volume, of 18,800 shares, the short-interest ratio is currently 1.6 days. Approximately 0.5% of the company's stock are short sold. View BIONDVAX PHARMA/S's Current Options Chain.

Some companies that are related to BIONDVAX PHARMA/S include Jounce Therapeutics (JNCE), La Jolla Pharmaceutical (LJPC), Solid Biosciences (SLDB), LogicBio Therapeutics (LOGC), Dyadic International (DYAI), Novavax (NVAX), Applied Genetic Technologies (AGTC), Windtree Therapeutics (WINT), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), X4 Pharmaceuticals (XFOR), Cidara Therapeutics (CDTX), Polarityte (PTE), Axcella Health (AXLA) and Gamida Cell (GMDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include Pluristem Therapeutics (PSTI), Exelixis (EXEL), Gilead Sciences (GILD), AbbVie (ABBV), BIOLINERX LTD/S (BLRX), Agilent Technologies (A), Agile Therapeutics (AGRX), Akari Therapeutics (AKTX), AVEO Pharmaceuticals (AVEO) and Anavex Life Sciences (AVXL).

(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BVXV stock can currently be purchased for approximately $10.25.

BIONDVAX PHARMA/S has a market capitalization of $66.93 million. The company earns $-23,410,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe.View Additional Information About BIONDVAX PHARMA/S.

The official website for BIONDVAX PHARMA/S is http://www.biondvax.com/.

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]